These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21630292)

  • 1. Serum prosaposin levels are increased in patients with advanced prostate cancer.
    Koochekpour S; Hu S; Vellasco-Gonzalez C; Bernardo R; Azabdaftari G; Zhu G; Zhau HE; Chung LW; Vessella RL
    Prostate; 2012 Feb; 72(3):253-69. PubMed ID: 21630292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification and overexpression of prosaposin in prostate cancer.
    Koochekpour S; Zhuang YJ; Beroukhim R; Hsieh CL; Hofer MD; Zhau HE; Hiraiwa M; Pattan DY; Ware JL; Luftig RB; Sandhoff K; Sawyers CL; Pienta KJ; Rubin MA; Vessella RL; Sellers WR; Sartor O
    Genes Chromosomes Cancer; 2005 Dec; 44(4):351-64. PubMed ID: 16080200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion.
    Hu S; Delorme N; Liu Z; Liu T; Velasco-Gonzalez C; Garai J; Pullikuth A; Koochekpour S
    Mol Cancer; 2010 Feb; 9():30. PubMed ID: 20132547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.
    Koochekpour S; Lee TJ; Sun Y; Hu S; Grabowski GA; Liu Z; Garay J
    J Cell Biochem; 2008 Aug; 104(6):2272-85. PubMed ID: 18481277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.
    Koochekpour S; Majumdar S; Azabdaftari G; Attwood K; Scioneaux R; Subramani D; Manhardt C; Lorusso GD; Willard SS; Thompson H; Shourideh M; Rezaei K; Sartor O; Mohler JL; Vessella RL
    Clin Cancer Res; 2012 Nov; 18(21):5888-901. PubMed ID: 23072969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.
    Foroozan M; Roudi R; Abolhasani M; Gheytanchi E; Mehrazma M
    Pathol Res Pract; 2017 Jun; 213(6):612-618. PubMed ID: 28552539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
    Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
    Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
    Hamami G
    Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.
    Ali A; Creevey L; Hao Y; McCartan D; O'Gaora P; Hill A; Young L; McIlroy M
    Breast Cancer Res; 2015 Sep; 17(1):123. PubMed ID: 26341737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues.
    Tribian LS; Lennartz M; Höflmayer D; de Wispelaere N; Dwertmann Rico S; von Bargen C; Kind S; Reiswich V; Viehweger F; Lutz F; Bertram V; Fraune C; Gorbokon N; Weidemann S; Hube-Magg C; Menz A; Uhlig R; Krech T; Hinsch A; Burandt E; Sauter G; Simon R; Kluth M; Steurer S; Marx AH; Lebok P; Dum D; Minner S; Jacobsen F; Clauditz TS; Bernreuther C
    Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity for prostate-specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: relation to progression following radical prostatectomy.
    Sauvageot J; Epstein JI
    Prostate; 1998 Jan; 34(1):29-33. PubMed ID: 9428385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population.
    Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
    PLoS One; 2011 May; 6(5):e19284. PubMed ID: 21559289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of tumour NSD2 expression in advanced prostate cancer.
    Stangl-Kremser J; Lemberger U; Hassler MR; Garstka N; Grubmüller B; Haitel A; Enikeev DV; Glybochko PV; Kramer G; Susani M; Shariat SF
    Biomarkers; 2020 May; 25(3):268-273. PubMed ID: 32091270
    [No Abstract]   [Full Text] [Related]  

  • 17. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
    Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
    Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?
    Heidegger I; Höfer J; Luger M; Pichler R; Klocker H; Horninger W; Steiner E; Jochberger S; Culig Z
    Prostate; 2015 Dec; 75(16):1904-9. PubMed ID: 26306920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.